医学前沿学术报告第 147期— Interleukin-12 (IL-12): A Retrospective

Maurice K. Gately, Associate Vice President, Sanofi-Aventis Pharmaceuticals , U.S.A

发布人:中山医学院

  目:   Interleukin-12 (IL-12): A Retrospective

主讲人:Maurice K. Gately, Associate Vice President, Sanofi-Aventis Pharmaceuticals , U.S.A

主 持 人:吴长有教授

         中山医学院免疫学教研室主任/免疫学研究所 所长

   间:2013 4 26日(星期五) 下午 1500

   点:中山大学北校区永生楼四楼讲学厅


主讲人简介:

 

Dr. Maurice K. Gately is Associate Vice President of Sanofi-Aventis Pharmaceuticals. He received his M.D., and Ph.D. degrees from Johns Hopkins University and Postdoctoral fellowship of immunology in Harvard Medical School. Dr. Maurice K. Gately is Project Leader and Manager for managing a portfolio of Development Projects in the Areas of Inflammatory and Respiratory Diseases.

Dr. Maurice K. Gately discovered interlukin-12 (IL-12) in the world.  He cloned murine and human IL-12 and knocked out IL-12 from mouse. He cloned IL-12 receptors, knocked out IL-12 receptors from mouse and made antibodies against human IL-12 and IL-12 receptors.  He was interested in the study of the production and biological function, the regulation as well as the clinical application of IL-12.  He is one of the most authoritative scientists in the study of IL-12, differentiation of T cells and cellular immunity.

 

 

欢迎各位师生踊跃参加!

中山大学中山医学院

中山大学医学科学处

   2013328